SG11201708075RA - Treatment of chronic graft versus host disease with syk inhibitors - Google Patents

Treatment of chronic graft versus host disease with syk inhibitors

Info

Publication number
SG11201708075RA
SG11201708075RA SG11201708075RA SG11201708075RA SG11201708075RA SG 11201708075R A SG11201708075R A SG 11201708075RA SG 11201708075R A SG11201708075R A SG 11201708075RA SG 11201708075R A SG11201708075R A SG 11201708075RA SG 11201708075R A SG11201708075R A SG 11201708075RA
Authority
SG
Singapore
Prior art keywords
treatment
host disease
versus host
graft versus
chronic graft
Prior art date
Application number
SG11201708075RA
Other languages
English (en)
Inventor
Paolo Julie A Di
Joseph Haw-Ling Lin
Shao-Lee Lin
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of SG11201708075RA publication Critical patent/SG11201708075RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201708075RA 2015-04-21 2016-04-19 Treatment of chronic graft versus host disease with syk inhibitors SG11201708075RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562150691P 2015-04-21 2015-04-21
PCT/US2016/028303 WO2016172117A1 (fr) 2015-04-21 2016-04-19 Traitement de la maladie chronique du greffon contre l'hôte avec inhibiteurs syk

Publications (1)

Publication Number Publication Date
SG11201708075RA true SG11201708075RA (en) 2017-11-29

Family

ID=55854820

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201708075RA SG11201708075RA (en) 2015-04-21 2016-04-19 Treatment of chronic graft versus host disease with syk inhibitors

Country Status (14)

Country Link
US (1) US20160375019A1 (fr)
EP (1) EP3285808A1 (fr)
JP (1) JP2018513173A (fr)
KR (1) KR20170137200A (fr)
CN (1) CN107530354A (fr)
AU (1) AU2016252387A1 (fr)
BR (1) BR112017022323A2 (fr)
CA (1) CA2983611A1 (fr)
EA (1) EA201791946A1 (fr)
HK (2) HK1244453A1 (fr)
MX (1) MX2017013496A (fr)
SG (1) SG11201708075RA (fr)
TW (1) TW201711685A (fr)
WO (1) WO2016172117A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101743784B1 (ko) 2008-12-08 2017-06-05 질레드 코네티컷 인코포레이티드 이미다조피라진 ｓｙｋ 억제제
MX350010B (es) 2010-03-11 2017-08-23 Gilead Connecticut Inc Inhibidores syk de imidazopiridinas.
NZ715776A (en) 2013-07-30 2017-04-28 Gilead Connecticut Inc Polymorph of syk inhibitors
AU2014296184B2 (en) 2013-07-31 2017-04-27 Gilead Sciences, Inc. Syk inhibitors
WO2015084992A1 (fr) 2013-12-04 2015-06-11 Gilead Sciences, Inc. Procédés pour le traitement de cancers
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
NZ726365A (en) 2014-07-14 2018-06-29 Gilead Sciences Inc Combinations for treating cancers
US20170173034A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
EP3512519A1 (fr) 2016-09-14 2019-07-24 Gilead Sciences, Inc. Inhibiteurs de syk
JP7179743B2 (ja) * 2017-02-17 2022-11-29 オーエスイー・イミュノセラピューティクス 抗ＳＩＲＰｇ抗体の新規の使用
CA3073871A1 (fr) 2017-08-25 2019-02-28 Gilead Sciences, Inc. Polymorphes inhibiteurs de syk
US11746110B2 (en) 2018-07-17 2023-09-05 Shenzhen Targetrx, Inc. Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity
WO2020172431A1 (fr) 2019-02-22 2020-08-27 Gilead Sciences, Inc. Formes solides de pyrazines condensées en tant qu'inhibiteur de syk
CN112939983A (zh) * 2021-02-01 2021-06-11 暨明医药科技（苏州）有限公司 一种SYK激酶抑制剂Lanraplenib的合成方法
WO2024124063A1 (fr) * 2022-12-09 2024-06-13 Kronos Bio, Inc. Formes cristallines de lanraplenib et leurs procédés de fabrication et d'utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037900B2 (en) * 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
WO2010068257A1 (fr) * 2008-12-08 2010-06-17 Cgi Pharmaceuticals, Inc. Inhibiteurs d'imidazopyrazine syk
US8450321B2 (en) * 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
NZ715776A (en) 2013-07-30 2017-04-28 Gilead Connecticut Inc Polymorph of syk inhibitors
EA201690127A1 (ru) 2013-07-30 2016-07-29 Джилид Коннектикут, Инк. Состав на основе ингибиторов syk
WO2015084992A1 (fr) * 2013-12-04 2015-06-11 Gilead Sciences, Inc. Procédés pour le traitement de cancers
TWI735853B (zh) * 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors

Also Published As

Publication number Publication date
HK1244453A1 (zh) 2018-08-10
CN107530354A (zh) 2018-01-02
TW201711685A (zh) 2017-04-01
JP2018513173A (ja) 2018-05-24
CA2983611A1 (fr) 2016-10-27
BR112017022323A2 (pt) 2018-07-03
US20160375019A1 (en) 2016-12-29
EP3285808A1 (fr) 2018-02-28
WO2016172117A1 (fr) 2016-10-27
HK1249054A1 (zh) 2018-10-26
EA201791946A1 (ru) 2018-03-30
MX2017013496A (es) 2018-02-09
AU2016252387A1 (en) 2017-10-19
KR20170137200A (ko) 2017-12-12

Similar Documents

Publication Publication Date Title
HK1249054A1 (zh) 使用syk抑制劑對慢性移植物抗宿主病的治療
HK1251408A1 (zh) 治療癌症的方法
ZA201804227B (en) Methods of treating cancer
IL253945A0 (en) kdm1a inhibitors to treat the disease
HK1254349A1 (zh) 用谷氨酰胺酶抑制劑治療肺癌
EP3122414A4 (fr) Traitement de maladie veineuse
ZA201706257B (en) Treatment of wood
ZA201607740B (en) Treatment of the complications of chronic liver disease with caspase inhibitors
IL278247B (en) mct4 inhibitors to treat the disease
EP3134436A4 (fr) Traitement de tumeurs provoquées par h-ras
HK1253238A1 (zh) 用於治療疾病的gls1抑制劑
HK1258611A1 (zh) 腹水的治療
PT3164394T (pt) Inibidores gls1 para o tratamento de doenças
HK1252245A1 (zh) 用於治療癌症的核苷酸
EP3134528A4 (fr) Arni à cibles multiples permettant le traitement de cancers
GB201408297D0 (en) Treatment of cancer
EP3313403A4 (fr) Traitement du cancer avec des inhibiteurs de dnapk
GB201417456D0 (en) Treatment of cancer
EP3854402C0 (fr) Traitement ou prévention de la maladie du greffon contre l'hôte
GB201512723D0 (en) Treatment of cancer
GB201507928D0 (en) Treatment of cancer
GB201504617D0 (en) Treatment of cancer
PT3851537T (pt) Tratamento da hiperbilirrubinemia
GB201504413D0 (en) Treatment of disease
GB201409362D0 (en) Treatment of cancer